Peptides community practice

Tesamorelin — Visceral Fat Reduction

Tesamorelin GHRH analogue for visceral fat reduction and body recomposition. FDA-approved for HIV-associated lipodystrophy; widely used off-label in anti-ageing communities. The only GHRH peptide with Phase III RCT data showing significant visceral fat reduction.

Duration

26 wk

Steps

2

Total Weeks

14

Route

SubQ

Protocols

1

Source

community practice

Protocol Timeline

Step Weeks Dose Compound Note
1 10 1 mg Tesamorelin 8-12 weeks on.
2 4 0 mg Tesamorelin 4 weeks off.

Rationale

Off-label anti-ageing use: 1–2mg/day SubQ in abdomen. IGF-1 monitoring recommended — IGF-1 should stay within upper-normal range, not exceed. Cycle: 26 weeks on, 8 weeks off. Visceral fat reduction visible on DEXA at 12–16 weeks.

Compounds Used

Tesamorelin

tesamorelin · primary

→

Related Tools

Medication Level Plotter

Simulate blood levels for this regimen

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide weekly totals into multiple injections

Track this regimen in Doseline

Adopt Tesamorelin — Visceral Fat Reduction as a template, set reminders for every step, and log doses as you go. All free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.